7 Recruiting Recurrent B-Cell Non-Hodgkin Lymphoma Phase 1 Clinical Trials
Active phase 1 studies for recurrent b-cell non-hodgkin lymphoma enrolling across the USA. Verify eligibility and contact site coordinators.
All Recurrent B-Cell Non-Hodgkin Lymphoma studiesPhase 1 Studies for Recurrent B-Cell Non-Hodgkin Lymphoma
🟢 Recruiting Phase1
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔ 🟢 Recruiting Phase1
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
📍 Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
📍 Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania
View Study & Checklist ➔